InSyBio DNA-seq has been launched allowing the discovery of genomic variants and their integration with other omics biomarkers

A new tool has been integrated in InSyBio Suite (InSyBio DNA-seq) which enables the fast and accurate pre-processing and analysis of DNA-sequencing data by non-bioinformatics experts with optimized pipelines. This tool includes the following functionalities:

  • Pre-processing of DNA-sequencing data with optimized pipelines and a user-friendly interface
  • Population analysis of genetics data for the identification of significant genomics biomarkers
  • Integration of genomic biomarkers with InSyBio Suite’s knowledge base to allow the biological interpretation of your data
  • Integration of genomic biomarkers with other omics biomarkers and clinical data using statistical and machine learning functionalities of InSyBio Biomarkers.

InSyBio’s CEO, Labros Digonis, stated that“Genomics is the area contributing more than 70% of the biomarkers used in clinical practice nowadays, being able to capture among other the predisposition for the development of complex diseases such as cancers and neurodegenerative diseases.
Considering the feedback of our users, we have now incorporated in InSyBio Suite a tool that allows non-bioinformatics experts to analyze their genomics data, identify, validate and interpret genomic biomarkers from them without the need of dedicated computing infrastructures.”

InSyBio is offering a free, one-month license to use InSyBio Suite’s all new tools and functionalities. Request your free trial now by completing a simple form at: .

About InSyBio: InSyBio is an international pioneer bioinformatics revolutionizing the medical field, clinical trials and food/nutrition industries through targeted biomarker discovery and highly-accurate predictive analytics.

Its solutions provide the R&D departments of Pharma, Research Institutes and Food/Nutrition companies, with the means both analytically and computationally to meet their challenging research and innovation goals (such as robust biomarker discovery and accurate predictive models). This is done through a sophisticated, software-as-a-service, machine learning platform which comprehensively integrates multi-omics data reducing the number of samples and additional validation experiments needed. Since 2013, InSyBio has worked with hundreds of academics, large and small companies, hospitals and research centers allowing them to succeed in their biomarker discovery tasks with an increase of at least 10% in predictive accuracy and decrease of at least 80% in overall time and cost.

Visit to see how InSyBio can help you reach your R&D goals in the era of Precision Medicine and Nutrition.

For more News visit our InSyBio Blog.

Scroll to top